KR20170057441A - Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법 - Google Patents

Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법 Download PDF

Info

Publication number
KR20170057441A
KR20170057441A KR1020177011477A KR20177011477A KR20170057441A KR 20170057441 A KR20170057441 A KR 20170057441A KR 1020177011477 A KR1020177011477 A KR 1020177011477A KR 20177011477 A KR20177011477 A KR 20177011477A KR 20170057441 A KR20170057441 A KR 20170057441A
Authority
KR
South Korea
Prior art keywords
thiadiazol
pyrrolo
pyrimidin
amino
methyl
Prior art date
Application number
KR1020177011477A
Other languages
English (en)
Korean (ko)
Inventor
피아오양 썬
구아일리 우
시아오후이 가오
융지앙 첸
링지아 쉔
Original Assignee
지앙수 헨그루이 메디슨 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 메디슨 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 메디슨 컴퍼니 리미티드
Publication of KR20170057441A publication Critical patent/KR20170057441A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y10S514/825—
KR1020177011477A 2014-10-09 2015-09-09 Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법 KR20170057441A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410529863.8 2014-10-09
CN201410529863.8A CN105566327A (zh) 2014-10-09 2014-10-09 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
PCT/CN2015/089223 WO2016054959A1 (zh) 2014-10-09 2015-09-09 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
KR20170057441A true KR20170057441A (ko) 2017-05-24

Family

ID=55652569

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177011477A KR20170057441A (ko) 2014-10-09 2015-09-09 Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법

Country Status (15)

Country Link
US (1) US10150770B2 (ja)
EP (1) EP3205653B1 (ja)
JP (1) JP6830888B2 (ja)
KR (1) KR20170057441A (ja)
CN (2) CN105566327A (ja)
AU (1) AU2015330554B2 (ja)
BR (1) BR112017005564A2 (ja)
CA (1) CA2963581C (ja)
DK (1) DK3205653T3 (ja)
ES (1) ES2836100T3 (ja)
HU (1) HUE052924T2 (ja)
PT (1) PT3205653T (ja)
RU (1) RU2704795C2 (ja)
TW (1) TWI675839B (ja)
WO (1) WO2016054959A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216790B1 (en) 2014-11-05 2019-10-02 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
CA3014090A1 (en) 2016-02-19 2017-08-24 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
MX2019002077A (es) * 2016-11-23 2019-05-15 Wuxi Fortune Pharmaceutical Co Ltd Formas cristalinas y formas de sal de compuestos de 7h-pirrolo[2,3-d]pirimidina y metodo de preparacion de las mismas.
TW201827436A (zh) * 2017-01-20 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
AU2021318201A1 (en) 2020-07-28 2023-02-02 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
JP2023550363A (ja) 2020-11-17 2023-12-01 アーキュティス・バイオセラピューティクス・インコーポレーテッド 深部皮膚薬物送達のための組成物および方法
TW202320788A (zh) * 2021-08-12 2023-06-01 大陸商江蘇恒瑞醫藥股份有限公司 用於治療或預防抗宿主病的吡咯并六元雜芳物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423120T1 (de) * 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US7432398B2 (en) * 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
EP2691395B1 (en) * 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
AU2012357296B2 (en) * 2011-12-21 2017-04-13 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof
KR102275326B1 (ko) * 2013-06-07 2021-07-12 지앙수 헨그루이 메디슨 컴퍼니 리미티드 야누스 키나제(jak) 억제제의 바이설페이트 및 그의 제조 방법

Also Published As

Publication number Publication date
EP3205653A4 (en) 2018-06-20
TWI675839B (zh) 2019-11-01
RU2017114689A3 (ja) 2019-01-22
US20180237438A1 (en) 2018-08-23
HUE052924T2 (hu) 2021-06-28
TW201613931A (en) 2016-04-16
JP6830888B2 (ja) 2021-02-17
DK3205653T3 (da) 2021-01-11
CA2963581A1 (en) 2016-04-14
AU2015330554B2 (en) 2020-01-02
JP2017530146A (ja) 2017-10-12
BR112017005564A2 (pt) 2017-12-12
CA2963581C (en) 2022-07-12
EP3205653A1 (en) 2017-08-16
EP3205653B1 (en) 2020-11-25
CN105980389A (zh) 2016-09-28
CN105980389B (zh) 2017-12-19
AU2015330554A1 (en) 2017-04-27
PT3205653T (pt) 2020-12-15
ES2836100T3 (es) 2021-06-24
RU2017114689A (ru) 2018-11-14
US10150770B2 (en) 2018-12-11
CN105566327A (zh) 2016-05-11
WO2016054959A1 (zh) 2016-04-14
RU2704795C2 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
KR20200134928A (ko) 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
JP6357100B2 (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の結晶性溶媒和物
AU2012283277B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
KR20230062916A (ko) 피마살탄 무수물 a형 결정다형 및 그 제조방법
TW202411221A (zh) 一種三嗪二酮類衍生物的晶型及製備方法
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right